Detalhe da pesquisa
1.
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.
Int J Mol Sci
; 20(9)2019 May 06.
Artigo
Inglês
| MEDLINE | ID: mdl-31064152
2.
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.
Am J Hematol
; 92(1): 82-87, 2017 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-27770583
3.
"On-demand" treatment with Thrombopoietin mimetics as "bridge to recovery" from chemotherapy in chronic immune thrombocytopenia patients with cancer. A single centre experience in nine patients.
Br J Haematol
; 181(3): 400-403, 2018 05.
Artigo
Inglês
| MEDLINE | ID: mdl-28466471
4.
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS).
J Clin Oncol
; 41(28): 4486-4496, 2023 10 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37294914
5.
Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI).
Leuk Lymphoma
; 63(1): 189-198, 2022 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34521299
6.
Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians.
Haematologica
; 96(5): 696-702, 2011 May.
Artigo
Inglês
| MEDLINE | ID: mdl-21330327
7.
BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors.
Front Oncol
; 9: 764, 2019.
Artigo
Inglês
| MEDLINE | ID: mdl-31456947
8.
High BCR-ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib.
Clin Cancer Res
; 23(23): 7189-7198, 2017 Dec 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28928163
9.
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
Lancet Haematol
; 4(3): e127-e136, 2017 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-28162984
10.
Quality of life and physicians' perception in myelodysplastic syndromes.
Am J Blood Res
; 2(2): 136-47, 2012.
Artigo
Inglês
| MEDLINE | ID: mdl-22762033
11.
Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life.
Leuk Lymphoma
; 51(6): 1007-14, 2010 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-20367566